See more : China Foods Limited (CHFHY) Income Statement Analysis – Financial Results
Complete financial analysis of Aerie Pharmaceuticals, Inc. (AERI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aerie Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Burke & Herbert Bank & Trust Company (BHRB) Income Statement Analysis – Financial Results
- Craneware plc (CRW.L) Income Statement Analysis – Financial Results
- NanoRepro AG (NNGRF) Income Statement Analysis – Financial Results
- Krungdhep Sophon Public Company Limited (KWC.BK) Income Statement Analysis – Financial Results
- Semler Scientific, Inc. (SMLR) Income Statement Analysis – Financial Results
Aerie Pharmaceuticals, Inc. (AERI)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.aeriepharma.com
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 194.13M | 83.14M | 69.89M | 24.18M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 26.85M | 25.33M | 4.83M | 641.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 167.29M | 57.81M | 65.06M | 23.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 86.17% | 69.53% | 93.08% | 97.35% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 75.84M | 74.01M | 91.38M | 86.12M | 72.08M | 52.39M | 44.45M | 29.87M | 11.88M | 9.27M | 10.70M |
| General & Administrative | 0.00 | 137.18M | 138.40M | 120.61M | 73.62M | 44.48M | 30.64M | 20.10M | 10.29M | 5.02M | 3.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 137.81M | 137.18M | 138.40M | 120.61M | 73.62M | 44.48M | 30.64M | 20.10M | 10.29M | 5.02M | 3.52M |
| Other Expenses | 0.00 | 2.30M | 22.77M | 26.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 213.64M | 213.50M | 252.55M | 233.28M | 145.69M | 96.87M | 75.09M | 49.97M | 22.17M | 14.29M | 14.22M |
| Cost & Expenses | 240.49M | 238.83M | 257.38M | 233.92M | 145.69M | 96.87M | 75.09M | 49.97M | 22.17M | 14.29M | 14.22M |
| Interest Income | 139.00K | 1.98M | 2.97M | 3.43M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 28.90M | 26.48M | 15.26M | 2.53M | 2.37M | 2.54M | 2.49M | 628.00K | 3.80M | 75.00K | 109.00K |
| Depreciation & Amortization | 37.50M | 34.16M | 18.11M | 2.44M | 1.41M | 970.00K | 252.00K | 73.00K | 64.00K | 138.00K | 120.00K |
| EBITDA | -7.81M | -117.22M | -166.30M | -227.59M | -143.09M | -95.36M | -71.48M | -47.43M | -27.29M | -14.77M | -12.74M |
| EBITDA Ratio | -4.02% | -141.00% | -237.96% | -941.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.31M | -155.69M | -187.49M | -209.74M | -145.69M | -96.87M | -75.09M | -49.97M | -22.17M | -14.29M | -14.22M |
| Operating Income Ratio | -23.34% | -187.27% | -268.27% | -867.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -28.90M | -22.17M | -12.18M | -22.82M | -1.17M | -1.99M | 862.00K | 1.84M | -8.98M | -685.00K | 1.25M |
| Income Before Tax | -74.22M | -177.86M | -199.67M | -232.57M | -146.86M | -98.87M | -74.22M | -48.13M | -31.15M | -14.98M | -12.97M |
| Income Before Tax Ratio | -38.23% | -213.93% | -285.70% | -961.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 593.00K | 5.25M | -90.00K | 3.00K | -1.76M | 193.00K | 139.00K | 2.47M | -5.18M | -610.00K | 1.36M |
| Net Income | -74.81M | -183.10M | -199.58M | -232.57M | -145.11M | -99.06M | -74.36M | -48.13M | -31.15M | -14.98M | -12.97M |
| Net Income Ratio | -38.54% | -220.24% | -285.57% | -961.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.61 | -3.99 | -4.39 | -5.58 | -4.11 | -3.40 | -2.88 | -2.00 | -6.29 | -0.95 | -0.82 |
| EPS Diluted | -1.61 | -3.99 | -4.39 | -5.58 | -4.11 | -3.40 | -2.88 | -2.00 | -6.29 | -0.95 | -0.82 |
| Weighted Avg Shares Out | 46.34M | 45.90M | 45.43M | 41.66M | 35.32M | 29.14M | 25.78M | 24.09M | 4.96M | 15.83M | 15.85M |
| Weighted Avg Shares Out (Dil) | 46.34M | 45.90M | 45.43M | 41.66M | 35.32M | 29.14M | 25.78M | 24.09M | 4.96M | 15.83M | 15.85M |
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives...
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022....
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to Aerie's Rhopressa®/netarsudil, AR-15512 in dry eye and “ROCK'Sters” anti-inflammatory programs will be...
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022)...
Aerie (AERI) Expands Market Presence Despite Stiff Competition
Aerie (AERI) is progressing well with the development of its ophthalmology pipeline. Its partnership with Santen Pharmaceuticals allows it to expand the presence of its drugs outside the United States.
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg,...
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
Aerie Pharmaceuticals (AERI) Stock: Why It Substantially Increased
The Aerie Pharmaceuticals Inc (NASDAQ: AERI) stock increased by 29.49% in the most recent trading session. This is why.
Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript
Aerie Pharmaceuticals, Inc. (AERI) CEO Raj Kannan on Q4 2021 Results - Earnings Call Transcript
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Source: https://incomestatements.info
Category: Stock Reports